Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation

Robert Zeiser; Dietrich W Beelen; Wolfgang Bethge; Martin Bornhäuser; Gesine Bug; Andreas Burchert; Maximilian Christopeit; Justus Duyster; Jürgen Finke; Armin Gerbitz; Jan Henning Klusmann; Guido Kobbe; Michael Lübbert; Carsten Müller-Tidow; Uwe Platzbecker; Wolf Rösler; Martin Sauer; Christoph Schmid; Thomas Schroeder; Mathias Stelljes; Nicolaus Kröger; Lutz P Müller

doi:10.1016/j.bbmt.2019.01.016

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation

Standard

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. / Zeiser, Robert; Beelen, Dietrich W; Bethge, Wolfgang; Bornhäuser, Martin; Bug, Gesine; Burchert, Andreas; Christopeit, Maximilian; Duyster, Justus; Finke, Jürgen; Gerbitz, Armin; Klusmann, Jan Henning; Kobbe, Guido; Lübbert, Michael; Müller-Tidow, Carsten; Platzbecker, Uwe; Rösler, Wolf; Sauer, Martin; Schmid, Christoph; Schroeder, Thomas; Stelljes, Mathias; Kröger, Nicolaus; Müller, Lutz P.

In: BIOL BLOOD MARROW TR, Vol. 25, No. 4, 04.2019, p. e128-e140.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Zeiser, R, Beelen, DW, Bethge, W, Bornhäuser, M, Bug, G, Burchert, A, Christopeit, M, Duyster, J, Finke, J, Gerbitz, A, Klusmann, JH, Kobbe, G, Lübbert, M, Müller-Tidow, C, Platzbecker, U, Rösler, W, Sauer, M, Schmid, C, Schroeder, T, Stelljes, M, Kröger, N & Müller, LP 2019, 'Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation', BIOL BLOOD MARROW TR, vol. 25, no. 4, pp. e128-e140. https://doi.org/10.1016/j.bbmt.2019.01.016

APA

Zeiser, R., Beelen, D. W., Bethge, W., Bornhäuser, M., Bug, G., Burchert, A., Christopeit, M., Duyster, J., Finke, J., Gerbitz, A., Klusmann, J. H., Kobbe, G., Lübbert, M., Müller-Tidow, C., Platzbecker, U., Rösler, W., Sauer, M., Schmid, C., Schroeder, T., ... Müller, L. P. (2019). Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. BIOL BLOOD MARROW TR, 25(4), e128-e140. https://doi.org/10.1016/j.bbmt.2019.01.016

Vancouver

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A et al. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. BIOL BLOOD MARROW TR. 2019 Apr;25(4):e128-e140. https://doi.org/10.1016/j.bbmt.2019.01.016

Bibtex

@article{330ba4fc70614edf8df29d3e162cf0b0,

title = "Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation",

abstract = "The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview of the established and evolving approaches to preventing or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of relapse. Established prophylactic measures to prevent relapse include optimized conditioning and graft-versus-host disease (GVHD) prophylaxis, as well as donor lymphocyte infusion (DLI) for high-risk patients; novel immunomodulatory interventions and maintenance approaches are still experimental. Improved diagnostics can detect persistent or recurring disease at a molecular level, enabling early preemptive interventions. Established options include hypomethylating agents and DLI. Standard treatments for hematologic relapse include chemotherapy, cessation of immunosuppressive treatment, and DLI. Experimental approaches include molecular targeted therapies, novel immunomodulatory treatments, and second allo-HCT. For all interventions, the potential risks, including occurrence of GVHD, must be weighed against the benefits individually in each patient. Concurrently, prevention and treatment of relapse after allo-HCT remain challenging and unmet medical needs.",

keywords = "Journal Article, Review",

author = "Robert Zeiser and Beelen, {Dietrich W} and Wolfgang Bethge and Martin Bornh{\"a}user and Gesine Bug and Andreas Burchert and Maximilian Christopeit and Justus Duyster and J{\"u}rgen Finke and Armin Gerbitz and Klusmann, {Jan Henning} and Guido Kobbe and Michael L{\"u}bbert and Carsten M{\"u}ller-Tidow and Uwe Platzbecker and Wolf R{\"o}sler and Martin Sauer and Christoph Schmid and Thomas Schroeder and Mathias Stelljes and Nicolaus Kr{\"o}ger and M{\"u}ller, {Lutz P}",

year = "2019",

month = apr,

doi = "10.1016/j.bbmt.2019.01.016",

language = "English",

volume = "25",

pages = "e128--e140",

journal = "BIOL BLOOD MARROW TR",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "4",

}

RIS

TY - JOUR

T1 - Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation

AU - Zeiser, Robert

AU - Beelen, Dietrich W

AU - Bethge, Wolfgang

AU - Bornhäuser, Martin

AU - Bug, Gesine

AU - Burchert, Andreas

AU - Christopeit, Maximilian

AU - Duyster, Justus

AU - Finke, Jürgen

AU - Gerbitz, Armin

AU - Klusmann, Jan Henning

AU - Kobbe, Guido

AU - Lübbert, Michael

AU - Müller-Tidow, Carsten

AU - Platzbecker, Uwe

AU - Rösler, Wolf

AU - Sauer, Martin

AU - Schmid, Christoph

AU - Schroeder, Thomas

AU - Stelljes, Mathias

AU - Kröger, Nicolaus

AU - Müller, Lutz P

PY - 2019/4

Y1 - 2019/4

N2 - The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview of the established and evolving approaches to preventing or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of relapse. Established prophylactic measures to prevent relapse include optimized conditioning and graft-versus-host disease (GVHD) prophylaxis, as well as donor lymphocyte infusion (DLI) for high-risk patients; novel immunomodulatory interventions and maintenance approaches are still experimental. Improved diagnostics can detect persistent or recurring disease at a molecular level, enabling early preemptive interventions. Established options include hypomethylating agents and DLI. Standard treatments for hematologic relapse include chemotherapy, cessation of immunosuppressive treatment, and DLI. Experimental approaches include molecular targeted therapies, novel immunomodulatory treatments, and second allo-HCT. For all interventions, the potential risks, including occurrence of GVHD, must be weighed against the benefits individually in each patient. Concurrently, prevention and treatment of relapse after allo-HCT remain challenging and unmet medical needs.

AB - The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview of the established and evolving approaches to preventing or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of relapse. Established prophylactic measures to prevent relapse include optimized conditioning and graft-versus-host disease (GVHD) prophylaxis, as well as donor lymphocyte infusion (DLI) for high-risk patients; novel immunomodulatory interventions and maintenance approaches are still experimental. Improved diagnostics can detect persistent or recurring disease at a molecular level, enabling early preemptive interventions. Established options include hypomethylating agents and DLI. Standard treatments for hematologic relapse include chemotherapy, cessation of immunosuppressive treatment, and DLI. Experimental approaches include molecular targeted therapies, novel immunomodulatory treatments, and second allo-HCT. For all interventions, the potential risks, including occurrence of GVHD, must be weighed against the benefits individually in each patient. Concurrently, prevention and treatment of relapse after allo-HCT remain challenging and unmet medical needs.

KW - Journal Article

KW - Review

U2 - 10.1016/j.bbmt.2019.01.016

DO - 10.1016/j.bbmt.2019.01.016

M3 - SCORING: Review article

C2 - 30658222

VL - 25

SP - e128-e140

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 4

ER -